Increased proteinase inhibitor-9 (PI-9) and reduced granzyme B in lung cancer: Mechanism for immune evasion?

Lung Cancer

Volumn 77, Issue 1, 2012, Pages 38-45

  Soriano, Cyd ^a,d   Mukaro, Violet ^a   Hodge, Greg ^a,d   Ahern, Jessica ^a   Holmes, Mark ^b,d   Jersmann, Hubertus ^a,b,d   Moffat, David ^b   Meredith, David ^b   Jurisevic, Craig ^c   Reynolds, Paul N ^a,b,d   Hodge, Sandra ^a,b,d  

^a HANSON INSTITUTE   (Australia)

^b Department of Thoracic Medicine ^*  (Australia)

^c ROYAL ADELAIDE HOSPITAL   (Australia)

^d UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

COPD; Granzyme B; Lung cancer; PI 9

Indexed keywords

GRANZYME B; GRANZYME B INHIBITOR; PROTEINASE INHIBITOR; PROTEINASE INHIBITOR 9; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; AGED; AIRWAY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CANCER TISSUE; CD8+ T LYMPHOCYTE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE EVASION; LUNG CANCER; LUNG LAVAGE; LUNG PARENCHYMA; LUNG RESECTION; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AGED; BRONCHOALVEOLAR LAVAGE FLUID; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; CD8-POSITIVE T-LYMPHOCYTES; CELL EXTRACTS; CELL LINE, TUMOR; CULTURE MEDIA, CONDITIONED; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; GRANZYMES; HUMANS; LUNG; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SERPINS; TUMOR ESCAPE;

EID: 84861722676     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.01.017     Document Type: Article

References (30)

1. The global burden of disease: Updated projections. Geneva: Health statistics and informatics Department, World Health Organisation; 2004.
2. Mannino D.M., Aguayo S.M., Petty T.L., Redd S.C. Low lung function and incident lung cancer in the United States: data from the First National Health and Nutrition Examination Survey follow-up. Arch Intern Med 2003, 163(12):1475-1480.
3. Alberg A.J., Samet J.M. Epidemiology of lung cancer. Chest 2003, 123(1 Suppl.):21S-49S.
4. Herbst R.S., Heymach J.V., Lippman S.M. Lung cancer. N Engl J Med 2008, 359(13):1367-1380.
5. National Cancer Institute SP: SEER Survival Monograph: Cancer Survival among Adults: U.S. SEER Program, 1988-2001, Patient and Tumor Charasteristics. Edited by Ries LAG YJ, Keel GE, Eisner MP, Lin YD, Horner MJ. Bethesda; 2007.
6. Milano F., Jorritsma T., Rygiel A.M., Bergman J.J., Sondermeijer C., Ten Brinke A., et al. Expression pattern of immune suppressive cytokines and growth factors in oesophageal adenocarcinoma reveal a tumour immune escape-promoting microenvironment. Scand J Immunol 2008, 68(6):616-623.
7. Young M.R., Wright M.A., Lozano Y., Matthews J.P., Benefield J., Prechel M.M. Mechanisms of immune suppression in patients with head and neck cancer: influence on the immune infiltrate of the cancer. Int J Cancer 1996, 67(3):333-338.
8. Liu K. Role of apoptosis resistance in immune evasion and metastasis of colorectal cancer. World J Gastrointest Oncol 2010, 2(11):399-406.
9. Bladergroen B.A., Strik M.C.M., Wolbink A.M., Wouters D., Broekhuizen R., Kummer J.A., et al. The granzyme B inhibitor proteinase inhibitor (PI9) is expressed by human mast cells. Eur J Immunol 2005, 35:1175-1183.
10. Buzza M.S., Hirst C.E., Bird C.H., Hosking P., McKendrick J., Bird P.I. The granzyme B inhibitor, PI-9, is present in endothelial and mesothelial cells, suggesting that it protects bystander cells during immune responses. Cell Immunol 2001, 210(1):21-29.
11. Medema J.P., de Jong J., Peltenburg L.T., Verdegaal E.M., Gorter A., Bres S.A., et al. Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors. Proc Natl Acad Sci USA 2001, 98(20):11515-11520.
12. Bladergroen B.A., Meijer C.J., ten Berge R.L., Hack C.E., Muris J.J., Dukers D.F., et al. Expression of the granzyme B inhibitor, protease inhibitor 9, by tumor cells in patients with non-Hodgkin and Hodgkin lymphoma: a novel protective mechanism for tumor cells to circumvent the immune system?. Blood 2002, 99(1):232-237.
13. van Houdt I.S., Oudejans J.J., van den Eertwegh A.J., Baars A., Vos W., Bladergroen B.A., et al. Expression of the apoptosis inhibitor protease inhibitor 9 predicts clinical outcome in vaccinated patients with stage III and IV melanoma. Clin Cancer Res 2005, 11(17):6400-6407.
14. ten Berge R.L., Meijer C.J., Dukers D.F., Kummer J.A., Bladergroen B.A., Vos W., et al. Expression levels of apoptosis-related proteins predict clinical outcome in anaplastic large cell lymphoma. Blood 2002, 99(12):4540-4546.
15. Rousalova I., Krepela E., Prochazka J., Cermak J., Benkova K. Expression of proteinase inhibitor-9/serpinB9 in non-small cell lung carcinoma cells and tissues. Int J Oncol 2010, 36(1):275-283.
16. Bossard C., Belhadj K., Reyes F., Martin-Garcia N., Berger F., Kummer J.A., et al. Expression of the granzyme B inhibitor PI9 predicts outcome in nasal NK/T-cell lymphoma: results of a Western series of 48 patients treated with first-line polychemotherapy within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. Blood 2007, 109(5):2183-2189.
17. Hodge S., Hodge G., Nairn J., Holmes M., Reynolds P.N. Increased airway granzyme b and perforin in current and ex-smoking COPD subjects. COPD 2006, 3(4):179-187.
18. Hodge S., Hodge G., Holmes M., Reynolds P.N. Increased airway epithelial and T-cell apoptosis in COPD remains despite smoking cessation. Eur Respir J 2005, 25(3):447-454.
19. World Health Organization classification of tumours. Pathology and genetics of tumours of the lung, pleura, thymus and heart 2004, IARC Press, Lyon. W.D. Travis, E. Brambilla, H.K. Muller-Hermlink, C.C. Harris (Eds.).
20. World Health Organization. The GOLD global strategy for the management and prevention of COPD. Available at (updated 2009). http://www.goldcopd.com/.
21. Hodge S.J., Hodge G.L., Holmes M., Reynolds P.N. Flow cytometric characterization of cell populations in bronchoalveolar lavage and bronchial brushings from patients with chronic obstructive pulmonary disease. Cytometry B Clin Cytom 2004, 61(1):27-34.
22. Hodge S., Hodge G., Scicchitano R., Reynolds P.N., Holmes M. Alveolar macrophages from subjects with chronic obstructive pulmonary disease are deficient in their ability to phagocytose apoptotic airway epithelial cells. Immunol Cell Biol 2003, 81(4):289-296.
23. Hodge G., Nairn J., Holmes M., Reynolds P.N., Hodge S. Increased intracellular T helper 1 proinflammatory cytokine production in peripheral blood, bronchoalveolar lavage and intraepithelial T cells of COPD subjects. Clin Exp Immunol 2007, 150(1):22-29.
24. Hodge S., Matthews G., Dean M.M., Ahern J., Djukic M., Hodge G., et al. Therapeutic role for mannose binding lectin in cigarette smoke-induced lung inflammation? Evidence from a Murine Model. Am J Respir Cell Mol Biol 2010, 42(2):235-242.
25. Hodge S., Matthews G., Mukaro V., Ahern J., Shivam A., Hodge G., et al. Cigarette smoke-induced changes to Alveolar Macrophage phenotype and function is improved by treatment with procysteine. Am J Respir Cell Mol Biol 2011, 44(5):673-681.
26. Hodge S., Hodge G., Ahern J., Liew C.L., Hopkins P., Chambers D.C., et al. Increased levels of T cell granzyme b in bronchiolitis obliterans syndrome are not suppressed adequately by current immunosuppressive regimens. Clin Exp Immunol 2009, 158(2):230-236.
27. Hodge S.J., Hodge G.L., Reynolds P.N., Holmes M.D. Differential rates of apoptosis in bronchoalveolar lavage and blood of lung transplant patients. J Heart Lung Transplant 2005, 24(9):1305-1314.
28. Kim G.G., Donnenberg V.S., Donnenberg A.D., Gooding W., Whiteside T.L. A novel multiparametric flow cytometry-based cytotoxicity assay simultaneously immunophenotypes effector cells: comparisons to a 4h 51Cr-release assay. J Immunol Methods 2007, 325(1-2):51-66.
29. U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999-2007. Incidence and Mortality Web-based Report. Atlanta (GA): Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute; 2010. Available at: http://www.cdc.gov/uscs.
30. Freeman C.M., Han M.K., Martinez F.J., Murray S., Liu L.X., Chensue S.W., et al. Cytotoxic potential of lung CD8(+) T cells increases with chronic obstructive pulmonary disease severity and with in vitro stimulation by IL-18 or IL-15. J Immunol 2010, 184(11):6504-6513.